31Aug/17

Is Bio-distribution Study Necessary for CAR-T Therapy?

August 31, 2017Immunotherapy ResearchCAR-T, CAR-T cell biodistribution studybiolabs

Biological therapy includes a variety of models, such as immunotherapy, gene therapy, regulation of angiogenesis therapy, small molecule targeting drugs and stem cells and tissue engineering regenerative medicine. Among them, cancer immunotherapyRead More…

22Aug/17

The Development of CAR Gene Construction

August 22, 2017Immunotherapy ResearchCAR gene constructs, car t generation, car t structure, CAR-T, universal car tbiolabs

CAR-T is chimeric antigen receptor T cell immunotherapy, which modifies T cell receptor by CAR and transforms it into the scFV segment in the binding domain of monoclonal antibodies. A classic CAR-TRead More…

17Aug/17

The Introduction of T Cell Proliferation Assay  

August 17, 2017Immunotherapy ResearchCAR-T, T cell proliferation assay, TCR T cell culturebiolabs

Cell proliferation is an important vital sign of the organism in a splitting manner. Single-celled organisms produce new individuals in the form of cell division, while a multicellular organism that produces newRead More…

16Aug/17

Revelation! CAR-T Has Its “Eyes” on Solid Tumor and the Treatment of That Would Be Possible

August 16, 2017Immunotherapy Research, Newscancer, CAR-T, immunotherapy, tumorbiolabs

Immunotherapy has become a new hope against cancer. CAR-T cell therapy is achieved by using genetic engineering method to express chimeric antigen receptors on T cells obtained from donner patients. These chimericRead More…

14Aug/17

Comparison between CAR-T and TCR-T

August 14, 2017Immunotherapy ResearchCAR-T, high affinity TCRbiolabs

As a matter of fact, tumor immunotherapy is divided into two categories. One is to show immune cells the tumor features, then direct them to locate and kill tumor cells. And anotherRead More…

12Aug/17

TCR, A New Star of Immune Cell Therapy

August 12, 2017Immunotherapy ResearchCAR-T, TCR service，tumor specific TCR，tcr t productionbiolabs

Immune cell therapy, the fourth major cancer treatment following surgery, radiotherapy, and chemotherapy, has been recognized as the most active and promising treatment in the comprehensive tumor treatment in the 21st century.Read More…

08Aug/17

Signal, Migration and Survival of CAR T Cells

August 8, 2017Immunotherapy Researchcar t establish, CAR-T, CAR-T therapybiolabs

CAR-T, Chimeric AntigenReceptor T-Cell Immunotherapy, is the most effective treatment of malignant tumors. Similar to other immunotherapy, its basic principle is to remove cancer cells in the use of the patient’s ownRead More…

08Aug/17

A New Immunotherapy Called CAR-T Will Beat Cancer Surprisingly

August 8, 2017Immunotherapy ResearchCAR T scFV, CAR-Tbiolabs

CAR-T (Chimeric Antigen Receptor T-Cell), as an immunocytotherapy regimen, has attracted a lot of attention from academics, doctors, patients, and investors worldwide. What does make it so attractive and popular? CAR-T modifiesRead More…

24Jul/17

The First CAR-T Therapy Drug Is Approved and Recommended by FDA Experts Unanimously on a 10-0 Vote!

July 24, 2017Immunotherapy Research, NewsCAR-T, FDA, immunotherapy drug, Novartisbiolabs

Novartis’ chimeric antigen receptor T cell therapy (CAR-T) was supported and approved unanimously (10-0) on July 12th by the U.S. FDA Advisory Committee experts. This vote marks the key milepost of thisRead More…

22Jun/17

Will the First CAR-T Therapy Be Approved on July 12? —Novartis CTL019

June 22, 2017Immunotherapy Research, NewsCAR-T, CAR-T therapy, CTL019, Novartisbiolabs

On July 12, FDA experts will discuss whether CAR-T CTL019 can be on the market, which is an assessment of the CTL019 Biologics License Application (BLA) submitted by Novartis and will evaluateRead More…